Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ACRX

ACRX - AcelRx Pharmaceuticals Inc Stock Price, Fair Value and News

1.22USD-0.03 (-2.40%)Market Closed
Watchlist

Market Summary

USD1.22-0.03
Market Closed
-2.40%

ACRX Stock Price

View Fullscreen

ACRX RSI Chart

ACRX Valuation

Market Cap

20.7M

Price/Earnings (Trailing)

-0.97

Price/Sales (Trailing)

0.22

EV/EBITDA

0.09

Price/Free Cashflow

-1.08

ACRX Price/Sales (Trailing)

ACRX Profitability

EBT Margin

70.36%

Return on Equity

-116.7%

Return on Assets

-91.84%

Free Cashflow Yield

-92.37%

ACRX Fundamentals

ACRX Revenue

Revenue (TTM)

84.1M

ACRX Earnings

Earnings (TTM)

-21.4M

Earnings Growth (Yr)

79.9%

Earnings Growth (Qtr)

68.95%

Breaking Down ACRX Revenue

Last 7 days

37.4%

Last 30 days

58.2%

Last 90 days

155.1%

Trailing 12 Months

-29.0%

How does ACRX drawdown profile look like?

ACRX Financial Health

Current Ratio

4.04

ACRX Investor Care

Shares Dilution (1Y)

127.57%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
202223.1M43.4M63.7M84.1M
20215.5M3.1M3.6M2.8M
20202.2M4.2M5.0M5.4M
20192.4M2.6M2.8M2.5M
20185.2M3.4M2.3M2.2M
201717.4M15.6M13.7M8.0M
201622.1M24.7M12.7M17.4M
20158.7M12.2M15.8M19.3M
201423.4M17.4M11.3M5.2M
20133.0M3.2M3.6M29.5M
20121.4M1.7M2.1M2.4M
20110001.1M

Tracking the Latest Insider Buys and Sells of AcelRx Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 13, 2023
angotti vincent j.
bought
7,268
0.7268
10,000
chief executive officer
Oct 10, 2023
hoffman stephen j
acquired
-
-
581
-
Oct 10, 2023
afable richard
acquired
-
-
581
-
Oct 10, 2023
adams adrian
acquired
-
-
581
-
Oct 10, 2023
broadfoot jill marie
acquired
-
-
581
-
Oct 10, 2023
rosen howard b
acquired
-
-
581
-
Oct 10, 2023
wan mark a
acquired
-
-
581
-
Oct 10, 2023
bozilenko marina
acquired
-
-
581
-
Sep 11, 2023
angotti vincent j.
bought
7,950
0.795
10,000
chief executive officer
Aug 25, 2023
palmer pamela p
sold
-8,104
1.089
-7,442
chief medical officer

1–10 of 50

Which funds bought or sold ACRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-21.24
-18.00
8,982
-%
Feb 15, 2024
Nantahala Capital Management, LLC
added
111
1,138,800
1,819,150
0.05%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
21,975
21,975
-%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
-
-
-%
Feb 14, 2024
CANTOR FITZGERALD, L. P.
added
1.00
3,079,580
3,488,480
0.72%
Feb 14, 2024
VANGUARD GROUP INC
added
3.09
30,531
130,170
-%
Feb 14, 2024
TANG CAPITAL MANAGEMENT LLC
unchanged
-
30,225
143,325
0.01%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-50.55
-9,219
15,473
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
reduced
-29.92
-4,621
36,666
-%

1–10 of 40

Are Funds Buying or Selling ACRX?

Are funds buying ACRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACRX
No. of Funds

Unveiling AcelRx Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
4.99%
890,346
SC 13G/A
Feb 13, 2024
lind global fund ii lp
4.2%
735,296
SC 13G/A
Jan 23, 2024
nantahala capital management, llc
11.8%
1,992,519
SC 13D
Aug 01, 2023
lind global fund ii lp
6.5%
1,102,944
SC 13G
Feb 14, 2023
armistice capital, llc
9.99%
864,328
SC 13G/A
Feb 15, 2022
armistice capital, llc
9.99%
12,314,479
SC 13G
Jan 27, 2022
bml investment partners, l.p.
0.0%
0
SC 13G/A
Jul 12, 2021
blackrock inc.
1.9%
2,266,040
SC 13G/A
Feb 10, 2021
bml investment partners, l.p.
5.3%
5,200,000
SC 13G/A
Jan 29, 2021
blackrock inc.
5.7%
5,640,946
SC 13G/A

Recent SEC filings of AcelRx Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
EFFECT
EFFECT
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
424B7
Prospectus Filed
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
S-3
S-3
Jan 29, 2024
D
D

Peers (Alternatives to AcelRx Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
386.5B
93.0B
-3.60% -2.76%
10.99
4.15
6.46% 95.94%
155.5B
23.6B
-3.76% -37.06%
-118.16
6.59
-28.02% -113.34%
152.8B
28.2B
-7.44% 18.02%
22.75
5.42
7.09% 2.52%
90.7B
27.4B
-17.13% -16.65%
15.44
3.31
0.94% 76.21%
14.6B
15.8B
15.02% 26.90%
-26.19
0.92
6.17% 77.01%
MID-CAP
4.9B
1.7B
14.11% 18.79%
13.7
2.93
49.61% 324.78%
4.3B
4.7B
-2.94% -9.06%
-1.1K
0.93
5.74% 96.18%
3.4B
8.5B
-0.23% 18.85%
-3.53
0.4
5.11% -479.13%
2.5B
601.3M
-0.28% 70.16%
18.15
4.08
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.9
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
20.7M
84.1M
58.23% -28.98%
-0.97
0.22
2882.68% -145.15%
17.6M
111.1M
-6.33% -18.68%
-1.1
0.16
-10.43% 84.90%
2.5M
20.0M
-35.83% -91.10%
-0.18
0.12
137.71% 66.04%

AcelRx Pharmaceuticals Inc News

Latest updates
Investing.com09 Jan 202408:00 am

AcelRx Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Revenue----84,052,00042,027,0002,0001,862,000443,000511,000738,0001,368,0002,924,000386,000294,000608,000941,000627,000613,000377,000818,000343,000
Costs and Expenses-9.5%5,328,0005,886,0004,523,0009,955,0004,936,000-12,112,00010,495,00010,458,0009,653,0009,982,00010,405,0009,758,00016,234,00015,467,00014,142,00014,302,00012,583,00011,590,0009,705,0007,971,0008,612,000
Operating Expenses------------------11,590,0009,705,0007,971,0008,612,000
  S&GA Expenses-18.1%4,281,0005,227,0003,724,0003,960,0004,100,000-9,490,0008,640,0008,694,0007,644,0007,846,0007,598,0007,575,00013,311,00012,786,00010,936,00011,329,0009,976,0007,648,0005,188,0003,944,0003,985,000
  R&D Expenses71.1%1,047,000612,000799,0001,094,000836,000-674,0001,416,000724,000969,000836,000956,000813,0001,412,0001,063,0001,058,0001,163,0001,377,0002,704,0003,642,0003,278,0003,513,000
EBITDA Margin-0.7%0.730.74-0.22-0.32-0.57-4.61-10.10-11.64-6.40-6.50-----------
Interest Expenses-36.7%119,000188,000245,000293,000390,000369,000538,000614,000672,000754,000824,000872,000855,000831,000828,000500,000376,000459,000529,000586,000643,000
Income Taxes100.0%--1,00011,0003,000---5,000---4,000---3,000---2,000-
Earnings Before Taxes-100.0%-3,885,000-6,739,00070,666,000-10,030,000-8,375,000-9,846,000--8,918,000-8,930,000-6,602,000--14,423,000-12,731,000-12,409,000--12,558,000-12,458,000-10,539,000-
EBT Margin0%0.700.70-0.27-0.39-0.74-6.08-11.36-13.19-7.29-7.45-----------
Net Income-8.9%-8,152,000-7,484,000-6,750,00070,663,000-8,674,000-7,917,000-8,375,000-9,851,000-8,956,000-8,918,000-8,930,000-6,606,000-15,925,000-14,423,000-12,731,000-12,412,000-13,674,000-12,558,000-12,458,000-10,541,000-11,592,000
Net Income Margin1.1%0.570.570.741.05-1.51-12.46-10.16-11.98-6.03-7.46-----------
Free Cashflow2.0%-5,350,000-5,461,000-5,396,000-8,815,000-9,023,000-8,032,000-4,127,000-9,938,000-9,732,000-7,958,000-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets31.2%23.0018.0026.0047.0048.0056.0072.0078.0072.0080.0087.0066.0066.0067.0077.0091.0010511511312178.00
  Current Assets63.2%14.009.0017.0025.0025.0032.0043.0050.0052.0059.0071.0047.0048.0049.0058.0072.0086.0097.0095.0010866.00
    Cash Equivalents80.7%13.007.0013.0015.0013.0015.0022.008.008.0021.0034.0022.0020.0022.0024.0015.0022.0065.0073.0088.0058.00
  Inventory----1.001.001.001.001.002.001.001.002.002.003.003.003.003.003.002.001.001.00
  Net PPE-----11.0011.0016.005.0016.0016.0016.0016.0014.0014.0015.0015.0014.0013.0012.0011.0011.00
Liabilities-32.2%5.007.0012.0026.0021.0023.00110114115116115122124128133133133134121116116
  Current Liabilities-15.3%4.004.009.0014.0016.0018.0017.0019.0017.0015.0016.0018.0017.0016.0016.0014.0011.008.0019.0016.0014.00
  Long Term Debt-------3.005.007.009.0011.0013.0015.0017.0019.0021.0022.0024.00-3.006.00
    LT Debt, Current---3.005.008.0010.009.008.009.009.009.009.009.009.007.005.002.00-10.009.008.00
    LT Debt, Non Current-------3.005.007.009.0011.0013.0015.0017.0019.0021.0022.0024.00-3.006.00
Shareholder's Equity75.7%18.0010.0014.0022.0027.0033.004444384234214203833723603593573553523514.00295
  Retained Earnings-0.3%-439-438-433-425-418-411-482-473-465-457-447-438-429-420-414-398-383-370-358-345-332
  Additional Paid-In Capital2.1%458449448448446445444438423421420383372360359357355352351349295
Shares Outstanding54.2%17.0011.0011.008.007.007.007.007.006.006.006.005.00---------
Float------36.00---161---95.00---197---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations44.5%-2,960-5,333-5,250-5,413-5,238-8,746-8,934-8,004-3,943-8,347-9,708-6,327-8,124-9,690-14,364-14,155-11,466-12,319-13,240-8,990-6,301
  Share Based Compensation-19.7%3784715696527017537831,1271,2211,1721,0891,0841,1041,0901,1461,2781,3261,3461,1071,2321,808
Cashflow From Investing-100.0%-2,7234002,6604,4429,17220,176-4,439-6,6522,393-17,4255,775-1,2146,92822,6506,889-33,206-10,617371-11,96010,714
Cashflow From Financing368.2%8,939-3,333-2,0725,296-1,637-2,083-2,08311,835-2,461-2,08234,2227,8537,5226659161.001,55014,695-1,79451,35919,880

ACRX Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Royalty revenue$ 117$ 0[1]$ 370$ 0[1]
Operating costs and expenses:    
Research and development1,178799[1]3,7772,729[1]
Selling, general and administrative2,2483,724[1]9,19911,784[1]
Impairment of property and equipment00[1]04,901[1]
Total operating costs and expenses3,4264,523[1]12,97619,414[1]
Other income (expense):    
Interest expense0(245)[1](134)(928)[1]
Interest income and other income, net1,893140[1]6,963229[1]
Non-cash interest income on liability related to the sale of future royalties00[1]01,136[1]
Gain on extinguishment of liability related to the sale of future royalties00[1]084,052[1]
Total other income (expense)1,893(105)[1]6,82984,489[1]
Provision for income taxes(2)(11)[1](5)(14)[1]
Net income (loss) from continuing operations(1,418)(4,639)[1](5,782)65,061[1]
Net income (loss) from discontinued operations – See Note 361(2,111)[1](8,098)(9,822)[1]
Net income (loss)(1,357)(6,750)[1](13,880)55,239[1]
Deemed dividends related to Series A Redeemable Convertible Preferred Stock0(186)0(186)
Income allocated to participating securities00[1]0(5,980)[1]
Net income (loss) attributable to Common Shareholders, basic(1,357)(6,936)[1](13,880)49,073[1]
Net income (loss) attributable to Common Shareholders, diluted$ (1,357)$ (6,936)[1]$ (13,880)$ 49,078[1]
Basic earnings (loss) per share    
Income (loss) from continuing operations (in dollars per share)$ (0.08)$ (0.65)[1]$ (0.45)$ 8.03[1]
Income (loss) from discontinued operations (in dollars per share)0(0.29)[1](0.63)(1.34)[1]
Net income (loss) per share (in dollars per share)(0.08)(0.94)[1](1.08)6.69[1]
Diluted earnings (loss) per share    
Income (loss) from continuing operations (in dollars per share)(0.08)(0.65)[1](0.45)8.02[1]
Income (loss) from discontinued operations (in dollars per share)0(0.29)[1](0.63)(1.34)[1]
Net income (loss) per share (in dollars per share)$ (0.08)$ (0.94)[1]$ (1.08)$ 6.68[1]
Shares used in computing net income (loss) per share of common stock, basic – See Note 10 (in shares)16,758,3227,377,363[1]12,880,3387,338,853[1]
Shares used in computing net income (loss) per share of common stock, diluted – See Note 10 (in shares)16,758,3227,377,363[1]12,880,3387,345,954[1]
Product [Member]    
Operating costs and expenses:    
Loss from operations$ (3,309)$ (4,523)[1]$ (12,606)$ (19,414)[1]
Contract and Other Collaboration [Member]    
Other income (expense):    
Net income (loss) before income taxes$ (1,416)$ (4,628)[1]$ (5,777)$ 65,075[1]
[1]The condensed consolidated statements of operations for the three and six months ended June 30, 2022 have been derived from the unaudited condensed consolidated financial statements for those periods included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, which were recast to reflect discontinued operations and filed with the Company’s Current Report on Form 8-K on August 1, 2023.

ACRX Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 13,389$ 15,275[1]
Restricted cash05,000[1]
Short-term investments0495[1]
Prepaid expenses and other current assets1,0171,865[1]
Assets of discontinued operations161,931[1]
Total current assets14,42224,566[1]
In-process research and development asset8,8198,819[1]
Other assets20166[1]
Assets of discontinued operations013,936[1]
Total Assets23,26147,487[1]
Current Liabilities:  
Accounts payable1,0261,256[1]
Accrued and other liabilities1,7922,531[1]
Long-term debt, current portion05,363[1]
Liabilities of discontinued operations, current portion7564,620[1]
Total current liabilities3,57413,770[1]
Warrant liability1,3807,098[1]
Other long-term liabilities0810[1]
Liabilities of discontinued operations03,995[1]
Total Liabilities4,95425,673[1]
Commitments and Contingencies
Common stock, $0.001 par value—200,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 16,952,269 and 8,243,680 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively[1]178
Additional paid-in capital[1]457,999447,635
Accumulated deficit[1](439,709)(425,829)
Total Stockholders’ Equity[1]18,30721,814
Total Liabilities and Stockholders’ Equity$ 23,261$ 47,487[1]
[1]The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, which were recast to reflect discontinued operations and filed with the Company’s Current Report on Form 8-K on August 1, 2023.
ACRX
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.
 CEO
 WEBSITEwww.acelrx.com
 EMPLOYEES19

AcelRx Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for AcelRx Pharmaceuticals Inc? What does ACRX stand for in stocks?

ACRX is the stock ticker symbol of AcelRx Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AcelRx Pharmaceuticals Inc (ACRX)?

As of Wed Feb 21 2024, market cap of AcelRx Pharmaceuticals Inc is 20.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRX stock?

You can check ACRX's fair value in chart for subscribers.

What is the fair value of ACRX stock?

You can check ACRX's fair value in chart for subscribers. The fair value of AcelRx Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AcelRx Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AcelRx Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACRX is over valued or under valued. Whether AcelRx Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact AcelRx Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRX.

What is AcelRx Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 21 2024, ACRX's PE ratio (Price to Earnings) is -0.97 and Price to Sales (PS) ratio is 0.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AcelRx Pharmaceuticals Inc's stock?

In the past 10 years, AcelRx Pharmaceuticals Inc has provided -0.2 (multiply by 100 for percentage) rate of return.